Akari Therapeutics plc ADR (0.01 USD)
$9.16
-$0.71 (-7.24%)
$9.16Day Range$10.13
Key Statistics
Market Cap
$17.83M
Shares Outstanding
1.9M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Dec 7, 2012
Round Lot
100
Locale
US
Trading Data
Day Open
$9.63
Day High
$10.13
Day Low
$9.16
Volume
63.7K
VWAP
$9.67
Prev Close
$9.88
Transactions
--
Acc. Volume
--
About Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
PHARMACEUTICAL PREPARATIONSSIC 28345 employees401 EAST JACKSON STREET, TAMPA, FL, 33602(929) 274-7510IPO Dec 7, 2012US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001541157
- Composite FIGI
- BBG003PMV495
- Share Class FIGI
- BBG003PMV510
- Ticker Root
- AKTX
- SIC Code
- 2834
About Akari Therapeutics plc ADR (0.01 USD) (AKTX) Stock
Akari Therapeutics plc ADR (0.01 USD) (AKTX) closed the 2026-09-18 session at $9.16, down 7.24% versus the previous close (-0.71). The stock opened at $9.63 and traded between $9.16 and $10.13 during that session. Session trading volume was 64K shares. The volume-weighted average price (VWAP) is $9.67.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics plc ADR (0.01 USD) has a market capitalization of $17.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AKTX is listed on the XNAS exchange. The company employs approximately 5 people. Akari Therapeutics plc ADR (0.01 USD) is headquartered in TAMPA, FL. The recorded listing date is 2012-12-07.
On this page you can find market AKTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.